Peptide news & updates
Follow regulatory developments, research context, and educational explainers without leaving the peptide review cycle to rumor.
regulatory
FDA Advisory Committee Votes to Recommend Six Peptides for Compounding
On July 23-24, 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A bulks list. Emideltide was not recommended.
Read more →
regulatory
FDA Announces July 2026 Advisory Committee for Peptide Review
Ahead of the vote, the FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026 to weigh seven peptides for the 503A bulks list. The committee ultimately recommended six of them.
Read more →
research
BPC-157: What the Research Shows About Gut Healing
BPC-157 remains one of the most discussed regenerative peptides, but the research story is strongest in gastrointestinal protection and ulcerative colitis-related models.
Read more →
education
Research Peptides vs Medical-Grade: Understanding the Difference
The biggest safety variable in peptide therapy is often not the peptide itself, but the quality controls around sourcing, pharmacy standards, and physician oversight.
Read more →